Controversial ALS Drug May Be Pulled from Market After Disappointing Trial Results

  • 📰 MedicineNet
  • ⏱ Reading Time:
  • 37 sec. here
  • 12 min. at publisher
  • 📊 Quality Score:
  • News: 53%
  • Publisher: 51%

Health News

ALS,Drug,Medication

Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. Amylyx Pharmaceuticals is considering voluntarily withdrawing the drug, Relyvrio/Albrioza, after it failed to help patients in a large follow-up study. The company has decided to pause promotion of the medication and will announce their plans for the drug in the next two months.

Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market. In a statement issued Friday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a large follow-up study, but the company stopped just short of saying it will definitely pull the drug from the market. The drug is sold as Albrioza in Canada.

"Amylyx intends to share plans for Relyvrio/Albrioza in ALS, which may include voluntarily withdrawing Relyvrio/Albrioza from the market," the company said in its statement. "At this time, Relyvrio/Albrioza and its related patient support program will continue to be available for people living with ALS. Amylyx has voluntarily decided to pause promotion of the medication during this time." Executives added that they were “surprised and disappointed” by the results and would announce their plans for the drug in the next two months. Relyvrio was first approved by the U.S. Food and Drug Administration in September 2022, following a lengthy, impassioned campaign by patients with ALS, a fatal muscle-wasting diseas

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 575. in BUSİNESS
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Business Business Latest News, Business Business Headlines